New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
15:22 EDTSURG, GEF, PPHM, ABM, TEA, LDRCompanies reporting After the Market Close on Monday, December 10
Notable companies reporting after the closing bell on Monday include ABM Industries (ABM), Greif (GEF), Landauer (LDR), Peregrine Pharmaceuticals (PPHM), Synergetics (SURG), and Teavana Holdings (TEA).
News For ABM;GEF;LDR;PPHM;SURG;TEA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
10:10 EDTLDRLandauer reports delay of 10-K filing, cites accounting control issues
Subscribe for More Information
10:08 EDTLDRLandauer sees FY14 revenue $155M, consensus $154M
Subscribe for More Information
10:06 EDTLDRLandauer sees FY15 revenue $153M-$163M, consensus $160.4M
Subscribe for More Information
05:41 EDTLDRLandauer reports preliminary Q4 revenue $42.3M, consensus $43.99M
Subscribe for More Information
December 11, 2014
09:16 EDTPPHMOn The Fly: Pre-market Movers
Subscribe for More Information
December 10, 2014
16:48 EDTGEFGreif sees FY14 operating profit $298M, consensus $2.21
Sees FY14 revenue $4.378B, consensus $4.44B.
16:47 EDTGEFGreif sees Q4 operating profit $93M, consensus 77c
Subscribe for More Information
16:10 EDTSURGSynergetics reports Q1 EPS 3c, consensus 2c
Subscribe for More Information
16:07 EDTPPHMPeregrine provides update on product development activities
Subscribe for More Information
16:06 EDTPPHMPeregrine reports Q2 EPS (7c), consensus (7c)
Subscribe for More Information
16:03 EDTSURGSynergetics acquires Sterimedix for $13.5M
Synergetics USA announced it has acquired Sterimedix, a private manufacturing company incorporated in England and Wales, for a net cash consideration of $13.5M. Sterimedix manufactures and distributes cannulas, needles and other disposable products for ophthalmic and aesthetic procedures. Sterimedix generated total revenue of approximately $6.4M during its fiscal year ended December 31, 2013. Sterimedix's sales are expected to grow approximately 15% on a constant currency basis for the calendar year ended December 31, 2014. Sterimedix is solidly profitable on an operating basis. In addition to the cash consideration, the agreement provides for potential gross profit margin earn-outs through December 31, 2017. Synergetics CEO David Hable said, "Sterimedix fits squarely within our strategy to identify strong ophthalmic businesses to enhance our company's long-term revenue growth and profitability. We anticipate the acquisition will be accretive to our fiscal 2015 operating and net income."
15:25 EDTPPHMNotable companies reporting after market close
Subscribe for More Information
08:18 EDTPPHMAvid Bioservices expands cGMP manufacturing capacity
Avid Bioservices, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries. The new production facility will more than double Avid Bioservices' current manufacturing capacity in a state-of-the-art facility design. This facility will employ an innovative and flexible modular clean room design and the latest in single-use technologies that provide expanded capacity to meet the growing needs of Avid's existing and future clients. The capacity expansion will take place within an existing 40,000 square foot warehouse located adjacent to the company's current campus. The new cGMP facility will accommodate multiple single use bioreactors of up to 2,000 liters, downstream processing suites, and dedicated support utilities that will allow for the production of a variety of biological products.
07:24 EDTABMImperial Capital to hold a conference
Subscribe for More Information
December 8, 2014
17:11 EDTABMABM Industries sees FY15 adjusted EPS $1.65-$1.75, consensus $1.80
For fiscal 2015, the company expects adjusted after-tax net income of $1.65-$1.75 per diluted share and after-tax net income of $1.45-$1.55 per diluted share. This guidance excludes potential benefits associated with the Work Opportunity Tax Credit, should Congress reenact the credit. The reenactment of the calendar 2014 WOTC could provide a benefit of 10c per diluted share in fiscal 2015. If Congress were to extend the WOTC for calendar 2015, the company could have a further benefit of 8c per diluted share.
17:09 EDTABMABM Industries reports Q4 adjusted EPS 52c, consensus 58c
Subscribe for More Information
15:19 EDTABMNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use